» Articles » PMID: 37572218

PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors

Overview
Date 2023 Aug 12
PMID 37572218
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer is a malignant tumor with higher morbidity and mortality. The purpose of this study is to investigate whether inhibition of Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) affects tumor cell proliferation, survival and migration in colon tumors with high Cyclin E1 (CCNE1) expression. PcDNA3.1-CCNE1 vector and si-PKMYT1 were transfected in SW480 cells by Lipofectamine 2000. Q-PCR and western blot assay were processed to detect the expression. Transwell assay and Edu assay were undertaken to verify the migration and proliferation. CCNE1 promotes the proliferation and migration of SW480. Silencing of PKMYT1 inhibited the proliferation of tumor cells. Silencing the expression of PKMYT1 under the premise of overexpression of CCNE1, the level of Cyclin Dependent Kinase 1 (CDK1)-PT14 was reduced, indicating that the cell cycle was blocked. The expression of γH2AX increased significantly, indicating that the DDR pathway of tumor cells was activated and DNA damage accumulated. The results of immunofluorescence microscopy showed significantly increased expression of DNA damage-associated marker (γH2AX: H2AX Variant Histone). In CCNE1 amplificated colorectal tumor cells, knockdown of PKMYT1 reduced cells in S phase, inhibited cell proliferation and promoted cell apoptosis, confirming that PKMYT1 was a potential therapeutic target for colorectal tumor. This study may verify a potential therapeutic target and provide a new idea for the treatment of colorectal cancer in the future.

Citing Articles

CKS1B as a potential target for prognostic assessment and intervention in pancreatic cancer and its role in abnormal proliferation and cellular phenotype through mediation of cell cycle signaling pathways.

Tang Y, Lan X, Yan M, Fu Z, Li H Saudi Med J. 2024; 45(2):128-138.

PMID: 38309745 PMC: 11115417. DOI: 10.15537/smj.2024.45.2.20230132.

References
1.
Kastrinos F, Syngal S . Recently identified colon cancer predispositions: MYH and MSH6 mutations. Semin Oncol. 2007; 34(5):418-24. PMC: 2259279. DOI: 10.1053/j.seminoncol.2007.07.005. View

2.
Sohrabi M, Zamani F, Ajdarkosh H, Rakhshani N, Ameli M, Mohamadnejad M . Prevalence of colorectal polyps in a group of subjects at average-risk of colorectal cancer undergoing colonoscopic screening in Tehran, Iran between 2008 and 2013. Asian Pac J Cancer Prev. 2014; 15(22):9773-9. DOI: 10.7314/apjcp.2014.15.22.9773. View

3.
Vacante M, Cristaldi E, Basile F, Borzi A, Biondi A . Surgical approach and geriatric evaluation for elderly patients with colorectal cancer. Updates Surg. 2019; 71(3):411-417. DOI: 10.1007/s13304-019-00650-3. View

4.
Busch O, Hop W, Hoynck van Papendrecht M, Marquet R, Jeekel J . Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993; 328(19):1372-6. DOI: 10.1056/NEJM199305133281902. View

5.
Tronov V, Kramarenko I, Maiorova E, Zakharov S . [Mismatch repair (MMR) efficiency and MSH2 gene mutation in human colorectal carcinoma cell line COLO320HSR]. Genetika. 2007; 43(4):537-44. View